(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions...
Stats | |
---|---|
今日成交量 | 6.46M |
平均成交量 | 1.77M |
市值 | 833 204 |
EPS | $0 ( 2024-03-29 ) |
下一个收益日期 | ( $0 ) 2024-05-16 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.00818 |
ATR14 | $0.00600 (26.55%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-18 | Hansen Maia | Sell | 67 | Common Stock |
2023-10-04 | Hansen Maia | Sell | 23 149 | Common Stock |
2023-10-04 | Camardo Daniel A. | Sell | 19 993 | Common Stock |
2023-09-18 | Hansen Maia | Sell | 67 | Common Stock |
2023-08-17 | Mayhugh Neema | Buy | 27 428 | NonQualified Stock Option (right to purchase) |
INSIDER POWER |
---|
23.17 |
Last 94 transactions |
Buy: 8 476 520 | Sell: 1 272 175 |
音量 相关性
Athersys Inc 相关性 - 货币/商品
Athersys Inc 财务报表
Annual | 2022 |
营收: | $5.33M |
毛利润: | $5.33M (100.00 %) |
EPS: | $-5.70 |
FY | 2022 |
营收: | $5.33M |
毛利润: | $5.33M (100.00 %) |
EPS: | $-5.70 |
FY | 2021 |
营收: | $5 514.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $0 |
FY | 2020 |
营收: | $1.44M |
毛利润: | $1.44M (100.00 %) |
EPS: | $-0.420 |
Financial Reports:
No articles found.
Athersys Inc
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。